Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers

Dec 08, 2020

In addition to ovarian and triple-negative breast cancers, TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

IND-enabling toxicity study concludes that TH1902 can be administered at 3 times the maximum tolerated dose of docetaxel alone

Significant potential to improve therapeutic window  

 Montreal, Canada – December 8, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced new pre-clinical in vivo findings regarding the efficacy and tolerability of its novel investigational proprietary peptide-drug conjugate (PDC), TH1902, for the treatment of several cancer types expressing the sortilin receptor (SORT1+) as shown in the table below.

New pre-clinical in vivo results in colorectal, pancreatic, melanoma and endometrial cancers are similar to those presented at the American Association for Cancer Research last June, which confirmed, at the time, the effect of TH1902 in vivo in ovarian and triple-negative breast cancers (TNBC). The Company intends to present the detailed results at scientific meetings next year.